Scientific Frontline: Extended "At a Glance" Summary: RAMP3's Role in Breast Cancer Immunity
The Core Concept: Receptor activity-modifying protein 3 (RAMP3) is a cellular protein that contributes to an immune-suppressing environment in breast tumors. Deleting the gene for this protein in mouse models results in fewer immune-suppressing macrophages, increased cancer-fighting CD8+ T cells, smaller primary tumors, and extended survival.
Key Distinction/Mechanism: Unlike treatments that directly target cancer cells, this approach alters the tumor microenvironment. Without RAMP3, macrophages avoid adopting an immune-suppressing state due to reduced activity in the IL-4/STAT6 signaling pathway and lower levels of the immune-suppressing molecule CCL8.
Major Frameworks/Components:
- RAMP3 as a regulator of the tumor microenvironment.
- Macrophage-driven immune exclusion versus CD8+ T cell tumor infiltration.
- The IL-4/STAT6 signaling pathway and MCP-family chemokine production in driving tumor progression.
- Synergistic effects with anti-programmed cell death protein 1 (PD-1) immunotherapy.
- Validation through human data from The Cancer Genome Atlas, linking RAMP3, CD163, and CD8A markers to poorer overall survival.
Branches of Science: Immunology, Molecular Oncology, Translational Medicine, Cellular Biology, and Immunopharmacology.
Future Application: Pharmacological agents designed to block or inhibit RAMP3 could be developed to reprogram the tumor microenvironment, thereby enhancing the efficacy of existing immunotherapies for patients with resistant breast cancer.
Why It Matters: Because the localized environment surrounding a tumor often prevents cancer-fighting immune cells from working effectively, identifying actionable targets like RAMP3 provides a critical pathway to make immunotherapy viable for a broader range of patients.
Researchers found that removing RAMP3 changed immune cells in mouse breast tumors and enhanced responses to immunotherapy.
A new study found that mice lacking RAMP3 had fewer immune-suppressing macrophages and an increased infiltration of cytotoxic CD8+ T cells in breast tumors. Researchers observed smaller tumors, less spread to the lungs, and longer survival. In a small experiment, these mice showed a greater survival benefit from anti-PD-1 immunotherapy. The findings suggest RAMP3 may be a potential target for future breast cancer treatment, but further studies are needed before its relevance to patients is known.
Cancer immunotherapy leverages the host immune system to target malignancies, though clinical efficacy remains variable among patient populations. One reason may be the environment surrounding a tumor. Macrophages normally clear damaged cells, but some can adopt an immunosuppressive phenotype within the tumor microenvironment, thereby inhibiting T cell-mediated cytotoxicity.
A research team, led by doctoral student Yan Zhang, along with Dr. Megumu Tanaka and Professor Takayuki Shindo from the Department of Cardiovascular Research at the Shinshu University School of Medicine in Japan, studied receptor activity-modifying protein 3 (RAMP3), which had previously been linked to stromal regulation in cancer. In mouse breast cancer models, they compared tumor growth, lung spread, survival, immune cells, and response to anti-programmed cell death protein 1 (PD-1) treatment when RAMP3 was present or genetically removed. They also analyzed single-cell and spatial data, as well as public breast cancer patient data.
Mice lacking RAMP3 developed smaller primary tumors, had less spread to the lungs, and lived longer than mice with the gene. Their tumors exhibited a reduction in macrophage-driven immune exclusion alongside a higher concentration of cytotoxic CD8+ T cells. These findings suggest that removing RAMP3 changed the tumor environment in ways that supported immune activity.
Further analyses offered clues about how this happens. Without RAMP3, macrophages were less likely to adopt an immunosuppressive phenotype. The researchers found reduced activity in the IL-4/STAT6 signaling pathway, which is involved in this process, and lower levels of CCL8, a molecule associated with immune suppression. In laboratory experiments, inhibiting MCP-family chemokine production reduced the tumor-promoting effect of macrophages on breast cancer cells, supporting a role for RAMP3-associated chemokine signaling in tumor progression.
The team also tested anti-PD-1 treatment, which helps immune cells attack cancer. In a small exploratory experiment with five mice per group, mice lacking RAMP3 showed a greater survival benefit from the treatment. This result is preliminary and requires confirmation.
“Immune cells can fight cancer, but the environment around a tumor can prevent them from working effectively,” says Dr. Tanaka. “We want to understand how to change that environment so these cells can do their job. Our findings in mice give us a reason to investigate RAMP3 further as a possible treatment target.”
The researchers also analyzed data from The Cancer Genome Atlas breast cancer cohort. A risk score combining RAMP3, CD163, a macrophage-associated marker, and CD8A, a marker linked to cytotoxic T cells, was associated with poorer overall survival. The association remained significant after adjustment for established clinicopathological factors. However, this does not prove that targeting RAMP3 would help patients or predict immunotherapy benefits.
“Our earlier work suggested that RAMP3 helps shape the environment around tumors, so we wanted to understand whether it also affects macrophages and response to immunotherapy,” says Ms. Zhang.
“The next step is to test whether a drug that blocks RAMP3 can reproduce the effects seen in mice lacking the gene,” says Prof. Shindo.
Overall, the study identifies RAMP3 as a possible contributor to immune suppression in breast tumors and supports further research into it as a treatment target. The research was mainly conducted in mice, and deleting a gene throughout the body differs from treatment with a drug. The exploratory in vivo immunotherapy data require validation in larger cohorts, and the retrospective human data do not establish prospective clinical efficacy. More research is needed to determine whether RAMP3 can be targeted safely and effectively in people.
Reference material: What Is: Macrophage
Funding: This work was supported by JST SOHATSU (JPMJFR220V), the JST FOREST Program, JSPS KAKENHI (24K10308, 25K10178, 23K06850, 24K02503, 24K22117), the YOKOYAMA Foundation for Clinical Pharmacology, the Japan Diabetes Foundation and Novo Nordisk Pharma Ltd., the Daiichi Sankyo Foundation of Life Science, the ONO Medical Research Foundation, the Life Science Foundation of Japan, the Yamaguchi Endocrine Research Foundation, Grants for Young Researchers from the Japan Association for Diabetes Education and Care, the Takahashi Industrial and Economic Research Foundation, The Aiba Works Medical Research Grant, the Takeda Science Foundation, the Japan Philanthropic Foundation, the Naito Foundation, the Otsuka Toshimi Scholarship Foundation, the Shinshu Public Utility Foundation for Promotion of Medical Sciences, the JST SPRING Program (JPMJSP2144), Project Mirai Cancer Research Grants, the TERUMO LIFE SCIENCE FOUNDATION, the Okinaka Memorial Institute for Medical Research, the Foundation for Promotion of Cancer Research, the Takeda Medical Research Foundation, and the Santen Pharmaceutical Educational Support Program.
Published in journal: Journal of Translational Medicine
Authors: Yan Zhang, Megumu Tanaka, Takayuki Sakurai, Akiko Kamiyoshi, Yuka Ichikawa-Shindo, Qianqian Guo, Ken Hoshiyama, Peixuan Li, Jiake Li, Jun Duan, Marina Hayashi, Kensuke Kai, Yunlu Zhao, Kun Dai, and Takayuki Shindo
Source/Credit: Shinshu University
Edited by: Scientific Frontline
Reference Number: imgy111626_02
